Polybrene improves transfection efficacy of recombinant replication-deficient adenovirus in cutaneous cells and burned skin

Journal of Gene Medicine

Volumn 8, Issue 2, 2006, Pages 138-146

  Jacobsen, F ^a   Hirsch, T ^a   Mittler, D ^a   Schulte, M ^a   Lehnhardt, M ^a   Druecke, D ^a   Homann, H H ^a   Steinau, H U ^a   Steinstraesser, Lars ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

galactosidase; Adenovirus; Burn; Gene transfer; Lipofection; Polybrene; Skin

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; BROXURIDINE; HEXADIMETHRINE BROMIDE; LIPID; LIPOFECTAMINE; PHOSPHATE BUFFERED SALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BURN; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE LOCATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; MATERIAL COATING; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; REPORTER GENE; SKIN CELL; TISSUE SECTION; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; BURNS; CELL LINE; GENE THERAPY; GENES, REPORTER; GENETIC VECTORS; HEXADIMETHRINE; HUMANS; LIPIDS; RATS; SKIN; TIME FACTORS; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; ANIMALIA;

EID: 32844468612     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.843     Document Type: Article

References (36)

1. Bowler PG. Wound pathophysiology, infection and therapeutic options. Ann Med 2002; 34: 419-427.
2. Margolis DJ, Crombleholme T, Herlyn M. Clinical protocol: phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen 2000; 8: 480-493.
3. Makinen K, Manninen H, Hedman M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002; 6: 127-133.
4. Somia N, Verma IM. Gene therapy: trials and tribulations. Nat Rev Genet 2000; 1: 91-99.
5. Lai CM, Lai YK, Rakoczy PE. Adenovirus and adeno-associated virus vectors. DNA Cell Biol 2002; 21: 895-913.
6. Mah C, Byrne BJ, Flotte TR. Virus-based gene delivery systems. Clin Pharmacokinet 2002; 41: 901-911.
7. Campain JA, Matassa AA, Felgner PL, et al. Lipid- and adenoviral-mediated gene transfer into AIDS-Kaposi's sarcoma cell lines. Cancer Gene Ther 1998; 5: 131-143.
8. Campbell C, Hultman S, Cairns B, et al. Green fluorescent protein-adenoviral construct as a model for transient gene therapy for human cultured keratinocytes in an athymic mouse model. J Trauma 2003; 54: 72-79; discussion 79-80.
9. Setoguchi Y, Jaffe HA, Danel C, et al. Ex vivo and in vivo gene transfer to the skin using replication-deficient recombinant adenovirus vectors. J Invest Dermatol 1994; 102: 415-421.
10. Nasz I, Adam E. Recombinant adenovirus vectors for gene therapy and clinical trials. Acta Microbiol Immunol Hung 2001; 48: 323-348.
11. Lotze MT, Kost TA. Viruses as gene delivery vectors: application to gene function, target validation, and assay development. Cancer Gene Ther 2002; 9: 692-699.
12. Mitani K, Kubo S. Adenovirus as an integrating vector. Curr Gene Ther 2002; 2: 135-144.
13. Ritter T, Lehmann M, Volk HD. Improvements in gene therapy: averting the immune response to adenoviral vectors. BioDrugs 2002; 16: 3-10.
14. Harvey BG, Worgall S, Ely S, et al. Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector. Hum Gene Ther 1999; 10: 2823-2837.
15. Chirmule N, Propert K, Magosin S, et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999; 6: 1574-1583.
16. Fasbender A, Zabner J, Chillon M, et al. Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J Biol Chem 1997; 272: 6479-6489.
17. Clark PR, Stopeck AT, Brailey JL, et al. Polycations and cationic lipids enhance adenovirus transduction and transgene expression in tumor cells. Cancer Gene Ther 1999; 6: 437-446.
18. Mizuno M, Ryuke Y, Yoshida J. Cationic liposomes conjugation to recombinant adenoviral vectors containing herpes simplex virus thymidine kinase gene followed by ganciclovir treatment reduces viral antigenicity and maintains antitumor activity in mouse experimental glioma models. Cancer Gene Ther 2002; 9: 825-829.
19. Natsume A, Mizuno M, Ryuke Y, et al. Cationic liposome conjugation to recombinant adenoviral vector reduces viral antigenicity. Jpn J Cancer Res 2000; 91: 363-367.
20. Yotnda P, Chen DH, Chiu W, et al. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther 2002; 5: 233-241.
21. Fallaux FJ, Kranenburg O, Cramer SJ, et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 215-222.
22. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994; 91: 4407-4411.
23. Steinstraesser L, Tack BF, Waring AJ, et al. Activity of novispirin G10 against Pseudomonas aeruginosa in vitro and in infected burns. Antimicrob Agents Chemother 2002; 46: 1837-1844.
24. Arcasoy SM, Latoche JD, Gondor M, et al. Polycations increase the efficiency of adenovirus-mediated gene transfer to epithelial and endothelial cells in vitro. Gene Ther 1997; 4: 32-38.
25. Doebis C, Ritter T, Brandt C, et al. Efficient in vitro transduction of epithelial cells and keratinocytes with improved adenoviral gene transfer for the application in skin tissue engineering. Transpl Immunol 2002; 9: 323-329.
26. Jensen UB, Petersen MS, Lund TB, et al. Transgene expression in human epidermal keratinocytes: cell cycle arrest of productively transfected cells. Exp Dermatol 2000; 9: 298-310.
27. Stadelmann WK, Digenis AG, Tobin GR. Physiology and healing dynamics of chronic cutaneous wounds. Am J Surg 1998; 176(Suppl 2A): 26S-38S.
28. Jacobsen F, Mittler D, Hirsch T, et al. Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections. Gene Ther 2005; in press; GT200400464.
29. Andree C, Swain WF, Page CP, et al. In vivo transfer and expression of a human epidermal growth factor gene accelerates wound repair. Proc Natl Acad Sci U S A 1994; 91: 12 188-12 192.
30. Eming SA, Whitsitt JS, He L, et al. Particle-mediated gene transfer of PDGF isoforms promotes wound repair. J Invest Dermatol 1999; 112: 297-302.
31. Jeschke MG, Barrow RE, Hawkins HK, et al. IGF-I gene transfer in thermally injured rats. Gene Ther 1999; 6: 1015-1020.
32. Yamasaki K, Edington HD, McClosky C, et al. Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated iNOS gene transfer. J Clin Invest 1998; 101: 967-971.
33. Steinstraesser L, Fohn M, Klein RD, et al. Feasibility of biolistic gene therapy in burns. Shock 2001; 15: 272-277.
34. Wiethoff CM, Middaugh CR. Barriers to nonviral gene delivery. J Pharm Sci 2003; 92: 203-217.
35. Zabner J, Fasbender AJ, Moninger T, et al. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 1995; 270: 18 997-19 007.
36. Wagner E. Effects of membrane-active agents in gene delivery. J Control Release 1998; 53: 155-158.